Radioligand Therapy 177Lu-PSMA-617 in Progressive PSMA-positive mCRPC

Andrew J. Armstrong, MD, MSc, provides insight on unmet needs and the use of androgen receptor inhibitors for patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Andrew J. Armstrong, MD, MSc, discusses the survival benefit of LuPSMA therapy in patients with metastatic castration-resistant prostate cancer and evaluates the response to therapy compared with other agents.

Dr Andrew J. Armstrong reviews the phase 3 VISION trial evaluating the use of LuPSMA therapy in patients with progressive PSMA-positive metastatic castrate-resistant prostate cancer.

An expert in prostate cancer comments on the appropriate patient population for Lutetium-177 PSMA-617 therapy for the management of metastatic castration-resistant prostate cancer.

Dr Andrew J. Armstrong reviews the safety of LuPSMA therapy as compared to cabazitaxel as seen in the phase 2 TheraP trial and comments on sequencing strategies for patients with metastatic castration-resistant prostate cancer.